Molim sve dr sa foruma i druge forumase ako nesto vise znaju o ovoj metodi za destrukciju mioma magnetnom rezonancom vodjenom ultrazvukom da nesto vise napisu i gde se to radi??
Todora
MRgFUS metoda???
Moderatori: vlada99, moderato, admin, dr Presetnik
-
PedjaDj
- Stalni član
- Postovi: 1058
- Pridružio se: Uto Jan 11, 2005 11:01 pm
- Koliki je zbir brojeva cetiri i pet: 5
- Lokacija: Beograd
odgovor
Draga Todora,
za sada se ova metoda na žalost ne radi kod nas što ne znači da jednog dana neće.
Za ObGyn: Draga koleginice, ne na nekom Američkom sajtu nego na ObGyn.net-u!
Znam da se ova neoperativna metoda ne koristi u Kanadi, ali se već više od godinu dana primenjuje na više renomiranih ustanova u Americi NPR:
-Johns Hopkins Hospital, Baltimore; (ima li "jače" u svetu?)
-Mayo Clinic;
-Lahey Clinic in Boston;
Radnet Management in Beverly Hills, Calif. te sam je pomenuo informativno.
Savetovali ste ženama u jednom od postova embolizaciju mioma za koju se zna da daje previše komplikacija, ne vidim zašto ja ne bih pomenuo ovu vrlo zanimljivu metodu destrukcije mioma fokusiranim ultrazvučnim talasom.
IZVINJAVAM SE ŠTO JE TEKST BEZ PREVODA:
MRgFUS relieves fibroid symptoms
Bruce K. Dixon
CHICAGO -- The first noninvasive therapy for the treatment of uterine fibroids provides symptom relief for 1 year and beyond without serious side effects, according to a clinical trial of MR-guided focused ultrasound surgery presented at the annual meeting of the Radiological Society of North America.
"The purpose of this study was to evaluate an expanded protocol using MR-guided focused ultrasound surgery [MRgFUS] for the treatment of symptomatic uterine fibroids," said Dr. Fiona M. Fennessy of the Brigham and Women's Hospital in Boston.
"Initially, we treated up to 2 hours and in the expanded protocol we treated up to 3 hours and increased the volume of fibroid treated from 100 to 150 cc, which means we're now treating fibroids up to 7 cm in diameter," she said. "We've shown that patients get a significant reduction of symptoms at 1 year, and our preliminary clinical reports suggest this extends up to 24 months."
During the procedure the patient lies prone with her uterus directly over a transducer that is situated within the MRI table. High-intensity ultrasound waves from the transducer heat and kill fibroid tissue, Dr. Fennessy said. "The role of MRI is to direct the beam and we can see exactly where the target is, and the MR also monitors the temperature within the fibroid; we also can monitor normal tissue to make sure it isn't damaged."
The availability of 3-D scanning allows the radiologist to make sure no bowel lies between the transducer and the target tissue. Later, results of the procedure are checked by injecting a contrast agent that is not absorbed by dead tissue, which shows up as a black spot on the radiograph.
A total of 149 patients were treated at five centers, including Johns Hopkins Hospital, Baltimore; the Mayo Clinic; the Lahey Clinic in Boston; and Radnet Management in Beverly Hills, Calif. Of these, 105 were treated under the initial guidelines, and 44 were treated under the expanded guidelines. The mean age in both cohorts was about 45 years and 90% of the women were white. Symptom improvement was based on the Uterine Fibroid Quality of Life Questionnaire. A healthy person without fibroid symptoms would score about 22 in a range of 1-100, Dr. Fennessy explained.
"Patients we evaluated for this trial had a mean baseline score of 62. At 3, 6, and 12 months, symptoms were reduced by nearly half, falling to 35 at 3 months and to 33 at 6 and 12 months," she said, adding that the percentage of patients with significant improvement went from 76% under the initial protocol to 86% in the expanded protocol.
"We also found that the greater the fibroid volume treated, the better the outcome. The goal is not to get rid of the fibroid altogether, but rather to kill the tissue in the center of the lesion so that it can collapse in on itself. And we found no difference in outcome whether we treated a single fibroid or multiple fibroids. Time was the limiting factor; we treated as many as we possibly could within the 3-hour time period allowed by the FDA when we did the study," Dr. Fennessy said.
Now that the system--the ExAblate 2000 (InSightec Inc.)--is available commercially, longer treatment periods are possible, she said. The only adverse events that the researchers encountered were position-related discomfort and sonication-related pain, which disappeared immediately after treatment stopped.
Dr. Fennessy attributes much of the study's success to cooperation between radiologists and the gynecologists who evaluate patients and refer them for treatment. Patients may still choose my-omectomy, which removes the problem completely, but she said MRgFUS is a good option for those who prefer a less invasive treatment. "If they want something more definitive, then surgery would be the option."
Though the desire for future pregnancy was exclusionary in this trial, a few patients who had MRgFUS have since become pregnant. "At the Brigham and Women's Hospital, two of our treated patients had full-term deliveries without problems, and throughout the world, there have been additional babies delivered to women who have undergone this procedure," she said.
BY BRUCE K. DIXON
Chicago Bureau
Percentage of Patients Showing Significant Improvement in Symptoms
Initial Guidelines Expanded Guidelines
(n = 105) (n = 44)
3 months 76.5% 86.4%
6 months 76.5% 85.7%
12 months 75.8% 85.7%
Source: Dr. Fennessy
COPYRIGHT 2006 International Medical News Group
Pozdrav i dobro zdravlje DrPeđaDj
za sada se ova metoda na žalost ne radi kod nas što ne znači da jednog dana neće.
Za ObGyn: Draga koleginice, ne na nekom Američkom sajtu nego na ObGyn.net-u!
Znam da se ova neoperativna metoda ne koristi u Kanadi, ali se već više od godinu dana primenjuje na više renomiranih ustanova u Americi NPR:
-Johns Hopkins Hospital, Baltimore; (ima li "jače" u svetu?)
-Mayo Clinic;
-Lahey Clinic in Boston;
Radnet Management in Beverly Hills, Calif. te sam je pomenuo informativno.
Savetovali ste ženama u jednom od postova embolizaciju mioma za koju se zna da daje previše komplikacija, ne vidim zašto ja ne bih pomenuo ovu vrlo zanimljivu metodu destrukcije mioma fokusiranim ultrazvučnim talasom.
IZVINJAVAM SE ŠTO JE TEKST BEZ PREVODA:
MRgFUS relieves fibroid symptoms
Bruce K. Dixon
CHICAGO -- The first noninvasive therapy for the treatment of uterine fibroids provides symptom relief for 1 year and beyond without serious side effects, according to a clinical trial of MR-guided focused ultrasound surgery presented at the annual meeting of the Radiological Society of North America.
"The purpose of this study was to evaluate an expanded protocol using MR-guided focused ultrasound surgery [MRgFUS] for the treatment of symptomatic uterine fibroids," said Dr. Fiona M. Fennessy of the Brigham and Women's Hospital in Boston.
"Initially, we treated up to 2 hours and in the expanded protocol we treated up to 3 hours and increased the volume of fibroid treated from 100 to 150 cc, which means we're now treating fibroids up to 7 cm in diameter," she said. "We've shown that patients get a significant reduction of symptoms at 1 year, and our preliminary clinical reports suggest this extends up to 24 months."
During the procedure the patient lies prone with her uterus directly over a transducer that is situated within the MRI table. High-intensity ultrasound waves from the transducer heat and kill fibroid tissue, Dr. Fennessy said. "The role of MRI is to direct the beam and we can see exactly where the target is, and the MR also monitors the temperature within the fibroid; we also can monitor normal tissue to make sure it isn't damaged."
The availability of 3-D scanning allows the radiologist to make sure no bowel lies between the transducer and the target tissue. Later, results of the procedure are checked by injecting a contrast agent that is not absorbed by dead tissue, which shows up as a black spot on the radiograph.
A total of 149 patients were treated at five centers, including Johns Hopkins Hospital, Baltimore; the Mayo Clinic; the Lahey Clinic in Boston; and Radnet Management in Beverly Hills, Calif. Of these, 105 were treated under the initial guidelines, and 44 were treated under the expanded guidelines. The mean age in both cohorts was about 45 years and 90% of the women were white. Symptom improvement was based on the Uterine Fibroid Quality of Life Questionnaire. A healthy person without fibroid symptoms would score about 22 in a range of 1-100, Dr. Fennessy explained.
"Patients we evaluated for this trial had a mean baseline score of 62. At 3, 6, and 12 months, symptoms were reduced by nearly half, falling to 35 at 3 months and to 33 at 6 and 12 months," she said, adding that the percentage of patients with significant improvement went from 76% under the initial protocol to 86% in the expanded protocol.
"We also found that the greater the fibroid volume treated, the better the outcome. The goal is not to get rid of the fibroid altogether, but rather to kill the tissue in the center of the lesion so that it can collapse in on itself. And we found no difference in outcome whether we treated a single fibroid or multiple fibroids. Time was the limiting factor; we treated as many as we possibly could within the 3-hour time period allowed by the FDA when we did the study," Dr. Fennessy said.
Now that the system--the ExAblate 2000 (InSightec Inc.)--is available commercially, longer treatment periods are possible, she said. The only adverse events that the researchers encountered were position-related discomfort and sonication-related pain, which disappeared immediately after treatment stopped.
Dr. Fennessy attributes much of the study's success to cooperation between radiologists and the gynecologists who evaluate patients and refer them for treatment. Patients may still choose my-omectomy, which removes the problem completely, but she said MRgFUS is a good option for those who prefer a less invasive treatment. "If they want something more definitive, then surgery would be the option."
Though the desire for future pregnancy was exclusionary in this trial, a few patients who had MRgFUS have since become pregnant. "At the Brigham and Women's Hospital, two of our treated patients had full-term deliveries without problems, and throughout the world, there have been additional babies delivered to women who have undergone this procedure," she said.
BY BRUCE K. DIXON
Chicago Bureau
Percentage of Patients Showing Significant Improvement in Symptoms
Initial Guidelines Expanded Guidelines
(n = 105) (n = 44)
3 months 76.5% 86.4%
6 months 76.5% 85.7%
12 months 75.8% 85.7%
Source: Dr. Fennessy
COPYRIGHT 2006 International Medical News Group
Pozdrav i dobro zdravlje DrPeđaDj
Re: MRgFUS metoda???
Nisam video da postoji posebna tema pa cu ostaviti poruku i ovde, pa neka moderatori odluce da li je potrebno jednu obrisati:
Proslo je dve godine i najnovija istrazivanja pokazuju uspesnost MRgFUS metode. Za sada najbliza klinika koja obavlja ovu intervenciju jeste u Dachau kod Minhena, a postoji i u Berlinu i Bohumu.
Posto sam i ja laik voleo bih neko dodatno misljenje od nasih strucnjaka o ovoj metodi i njenoj delotvornosti. Da li znate nekog strucnjaka (ime i prezime, kontakt) sa kime bi se mogli posavetovati, jer pre toga ne bi uspostavljali kontakt sa Nemcima. S obzirom da je intervencija ambulantna, i da nije potreban boravak u klinici, sporedni troskovi (smestaj, put i hrana) cini ovu metodu jako prihvatljivom u poredjenu sa operacijom.
hvala svima
Proslo je dve godine i najnovija istrazivanja pokazuju uspesnost MRgFUS metode. Za sada najbliza klinika koja obavlja ovu intervenciju jeste u Dachau kod Minhena, a postoji i u Berlinu i Bohumu.
Posto sam i ja laik voleo bih neko dodatno misljenje od nasih strucnjaka o ovoj metodi i njenoj delotvornosti. Da li znate nekog strucnjaka (ime i prezime, kontakt) sa kime bi se mogli posavetovati, jer pre toga ne bi uspostavljali kontakt sa Nemcima. S obzirom da je intervencija ambulantna, i da nije potreban boravak u klinici, sporedni troskovi (smestaj, put i hrana) cini ovu metodu jako prihvatljivom u poredjenu sa operacijom.
hvala svima